Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $171,998 | 3 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $171,998 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $793.94 | 1 | Lilly USA, LLC ($793.94) |
| 2023 | $171,204 | 2 | Lilly USA, LLC ($171,204) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/11/2024 | Lilly USA, LLC | — | — | Cash or cash equivalent | $793.94 | Research |
| Study: RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II AND III BRAF V600E COLON CANCER | ||||||
| 05/01/2023 | Lilly USA, LLC | — | — | Cash or cash equivalent | $128,232.00 | Research |
| Study: A PHASE III TRIAL OF IRINOTECAN 5-FU LEUCOVORIN OR OXALIPLATIN 5-FU LEUCOVORIN WITH BEVACIZUMAB OR CETUXIMAB C225 OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM | ||||||
| 04/24/2023 | Lilly USA, LLC | — | — | Cash or cash equivalent | $42,971.98 | Research |
| Study: RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II AND III BRAF V600E COLON CANCER | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III TRIAL OF IRINOTECAN 5-FU LEUCOVORIN OR OXALIPLATIN 5-FU LEUCOVORIN WITH BEVACIZUMAB OR CETUXIMAB C225 OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM | Lilly USA, LLC | $128,232 | 1 |
| RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II AND III BRAF V600E COLON CANCER | Lilly USA, LLC | $43,766 | 2 |
About Dr. Monica Bertagnolli, MD
Dr. Monica Bertagnolli, MD is a Surgery healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528024270.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Monica Bertagnolli, MD has received a total of $171,998 in payments from pharmaceutical and medical device companies, with $793.94 received in 2024. These payments were reported across 3 transactions from 1 company. The most common payment nature is "" ($171,998).
Practice Information
- Specialty Surgery
- Location Boston, MA
- Active Since 04/21/2006
- Last Updated 07/08/2007
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1528024270
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgery Doctors in Boston
Omar Kudsi, M.d, M.D
Surgery — Payments: $1.3M
Michael Tarnoff, M.d, M.D
Surgery — Payments: $1.1M
Dr. Kyle Eberlin, M.d, M.D
Surgery — Payments: $540,116
Dr. Ankit Mehta, M.d, M.D
Surgery — Payments: $272,678
Dr. Stephen Miller, M.d, M.D
Surgery — Payments: $212,688
Patricia Sylla, M.d, M.D
Surgery — Payments: $204,557